Related Experiment Video
Updated: Oct 9, 2025
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Antagonists targeting eEF2 kinase rescue multiple aspects of pathophysiology in Alzheimer's disease model mice
Nicole P Kasica1, Xueyan Zhou1, Qian Yang1
1Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Abstract:
It is imperative to develop novel therapeutic strategies for Alzheimer's disease (AD) and related dementia syndromes based on solid mechanistic studies. Maintenance of memory and synaptic plasticity relies on de novo protein synthesis, which is partially regulated by phosphorylation of eukaryotic elongation factor 2 (eEF2) via its kinase eEF2K. Abnormally increased eEF2 phosphorylation and impaired mRNA translation have been linked to AD. We recently reported that prenatal genetic suppression of eEF2K is able to prevent aging-related cognitive deficits in AD model mice, suggesting the therapeutic potential of targeting eEF2K/eEF2 signaling in AD. Here, we tested two structurally distinct small-molecule eEF2K inhibitors in two different lines of AD model mice after the onset of cognitive impairments. Our data revealed that treatment with eEF2K inhibitors improved AD-associated synaptic plasticity impairments and cognitive dysfunction, without altering brain amyloid β (Aβ) and tau pathology. Furthermore, eEF2K inhibition alleviated AD-associated defects in dendritic spine morphology, post-synaptic density formation, protein synthesis, and dendritic polyribosome assembly. Our results may offer critical therapeutic implications for AD, and the proof-of-principle study indicates translational implication of inhibiting eEF2K for AD and related dementia syndromes. Cover Image for this issue: https://doi.org/10.1111/jnc.15392.
Insights
Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small molecules improved cognitive function and synaptic plasticity in Alzheimer's disease (AD) mouse models. This approach offers a promising therapeutic strategy for AD and related dementias.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Alzheimer's disease (AD) pathogenesis involves impaired mRNA translation and synaptic plasticity.
- Eukaryotic elongation factor 2 kinase (eEF2K) regulates protein synthesis and synaptic function.
- Previous studies suggest targeting eEF2K/eEF2 signaling may be beneficial for AD.
Purpose of the Study:
- To investigate the therapeutic potential of small-molecule eEF2K inhibitors in established Alzheimer's disease mouse models.
- To evaluate the effects of eEF2K inhibition on cognitive deficits, synaptic plasticity, and underlying molecular mechanisms in AD.
Main Methods:
- Treatment of two different lines of AD model mice with two distinct small-molecule eEF2K inhibitors.
- Assessment of cognitive function, synaptic plasticity, dendritic spine morphology, and protein synthesis.
- Analysis of amyloid-beta (Aβ) and tau pathology.
Main Results:
- eEF2K inhibitors improved cognitive dysfunction and synaptic plasticity impairments in AD mice.
- Inhibition of eEF2K did not alter Aβ or tau pathology.
- Treatment alleviated defects in dendritic spine morphology, post-synaptic density, protein synthesis, and polyribosome assembly.
Conclusions:
- Small-molecule inhibition of eEF2K demonstrates therapeutic potential for Alzheimer's disease.
- Targeting eEF2K offers a promising strategy for improving cognitive function in AD by enhancing protein synthesis and synaptic plasticity.
- This study provides a proof-of-principle for the translational application of eEF2K inhibitors in treating AD and related dementias.
